A Prospective, Single-Arm, Multicenter, Pragmatic Phase-IV Trial Investigating Safety and Effectiveness of DARZALEX (Daratumumab) In Indian Subjects With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
Phase of Trial: Phase IV
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Johnson & Johnson
- 01 Jul 2019 Planned End Date changed from 21 Jan 2022 to 20 Jun 2021.
- 01 Jul 2019 Status changed from not yet recruiting to recruiting.
- 28 May 2019 Planned End Date changed from 22 Feb 2021 to 21 Jan 2022.